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Abstract
Introduction Bcl-2 antanogene-1 (Bag-1) binds the anti-
apoptotic mediator Bcl-2, and enhances its activity. Bcl-2 and
Bag-1 are associated with chemotherapy resistance in cancer
cells. Drugs that target Bcl-2 are currently in clinical
development. The purpose of the present study was to examine
expression patterns of Bag-1 in a large cohort of breast tumors
and to assess the association with Bcl-2, estrogen receptor,
progesterone receptor and Her2/neu, and other clinical/
pathological variables.
Methods Tissue microarrays containing primary specimens
from 638 patients with 10-year follow-up were employed, and
the expression of Bag-1, Bcl-2, estrogen receptor, progesterone
receptor and Her2/neu was assessed using our automated
quantitative analysis method. We used cytokeratin to define
pixels as breast cancer (tumor mask) within the array spot, and
we measured biomarker expression within the mask using Cy5
conjugated antibodies.
Results High Bcl-2 expression was associated with improved
survival in the entire cohort and in the node-positive subset (P =
0.008 and P = 0.002, respectively). High Bag-1 expression was
associated with improved survival in the node-positive subset (P
= 0.006). On multivariable analysis, neither Bcl-2 nor Bag-1
retained their independence as prognostic markers. Strong
associations were found between Bag-1, Bcl-2, estrogen
receptor and progesterone receptor.
Conclusion Bag-1 and Bcl-2 expression in breast tumors is
associated with improved outcome and steroid receptor
positivity. Evaluation of Bcl-2 and Bag-1 expression in breast
cancer may identify a subset of patients with a favorable
prognosis, who might not benefit from chemotherapy or who
might benefit from Bcl-2 targeting agents in addition to
antihormonal therapy.
Introduction
Breast cancer is the most common malignancy among
women, with a projected incidence of 178,480 new diag-
noses in the United States in 2007 [1]. Over 40,000 women
are expected to die from metastatic disease in 2007 [1]; adju-
vant systemic therapy is therefore given for early-stage disease
to decrease the risk of death from breast cancer.
A number of factors are used to assess the risk of developing
metastatic disease and death, including lymph node involve-
ment, tumor size, nuclear and histologic grade, age, hormone
receptor expression and Her2/neu status. Lymph node
involvement is the most reliable predictor of metastatic
relapse, yet within the lymph node-positive subset and the
lymph node-negative subset of patients there is variability in
prognosis, and we have no reliable means of determining
which patients will survive without adjuvant systemic therapy.
For example, it is well established that adjuvant chemotherapy
decreases the risk of recurrence in node-positive patients [2],
yet older studies showed that there is a subset of node-posi-
tive breast cancer patients, particularly those with estrogen
receptor (ER)-positive tumors, who survive with tamoxifen
alone [3]. There is therefore great need to identify new prog-
nostic markers that will assist in patient selection for adjuvant
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therapies. Moreover, these markers can assist in selection of
biospecific therapies once drugs that target these markers
become available.
A number of prior studies have assessed the prognostic value
of the anti-apoptotic mediator Bcl-2 in breast cancer [4-24].
Bcl-2 blocks apoptosis via the mitochondrial pathway by inhib-
iting the release of cytochrome C from the mitochondria, thus
preventing the cascade of events that results in compromise
of the mitochondrial outer membrane potential, which in turn
leads to caspase-9 activation and subsequent apoptosis [25].
Bcl-2 has been shown to inhibit chemotherapy-induced apop-
tosis, and chemotherapy resistance has been reversed in can-
cer cells treated with Bcl-2-targeting therapy [26]. Although
Bcl-2 is an anti-apoptotic protein, high Bcl-2 expression has
been observed in ER-positive breast cancers
[4,8,13,14,18,20,23,27-38], as well as in progesterone
receptor (PR)-positive breast cancers [4,13,14,27-31,33-39],
and has been associated with improved survival in breast can-
cer [4-24,40]. The largest of these studies – conducted by
Callagy and colleagues – included 930 cases, and showed
that positive Bcl-2 expression was a strong predictor of
improved survival, independent of the Nottingham prognostic
index [6]. High Bcl-2 expression has been associated with
improved prognosis even among patients at very high risk for
distant relapse, with over 10 involved lymph nodes [41].
Bcl-2 antanogene-1 (Bag-1) is a protein that has multiple cel-
lular functions. Bag-1 binds to Bcl-2 and enhances its anti-
apoptotic activity [42,43]. Bag-1 also has anti-apoptotic
effects that are independent of Bcl-2; it binds to multiple
receptor tyrosine kinases and enhances their ability to inhibit
apoptosis [44], and it interacts with the heat shock proteins
HSC70 and HSP70 [45]. Bag-1 modulates the function of the
ER, and enhances estrogen-dependent transcription [46]. By
binding to its partners and regulating their function, Bag-1
therefore modulates pathways necessary for transcription and
cell growth and survival, as reviewed by Townsend and col-
leagues [47].
The Bag-1 gene has four protein isoforms, three major iso-
forms (p50, p46 and p33 – Bag-1L, Bag-1M and Bag-1S,
respectively) and one minor isoform (p29) [48,49]. The iso-
forms arise from a single mRNA by alternative translation initi-
ation [50,51]. The distinct isoforms are associated with
different subcellular locations and have variable functions
[49,52]. Bag-1L is localized to the nucleus, whereas Bag-1M
and Bag-1S are generally found in the cytoplasm. In some cell
types and in conditions of stress, however, Bag-1M may also
be localized to the nucleus [49,52].
Several preclinical studies have demonstrated the importance
of Bag-1 in breast cancer [19,42,53-60]. In breast cancer cell
lines, Bag-1 prevents cells from undergoing apoptosis and
protects cells from other forms of stress, including radiation,
chemotherapy and hypoxia [61]. ZR-75-1 breast cancer cells
stably transfected with Bag-1 have increased survival in cul-
ture, and form larger tumors than nontransfected cells when
injected into mammary fat pads of mice [62]. ZR-75-1 cells
stably expressing mutated forms of Bag-1 display retarded
growth in vivo and in vitro [62], suggesting that targeting Bag-
1 might be a useful strategy for treating breast cancer.
A number of relatively small cohort studies have assessed
expression of Bag-1 in breast cancer [19,42,52-60,63], with
divergent results. For example, Tang and colleagues studied
140 breast tumors and found an association between high
nuclear Bag-1 expression and decreased survival [58],
Townsend and colleagues found no significant association
between nuclear or cytoplasmic Bag-1 and survival in 160
patients [59], and Turner and colleagues found a strong asso-
ciation between high cytoplasmic Bag-1 and improved survival
[60].
Similarly, reported associations between Bag-1 and Bcl-2, ER
and PR are variable; some researchers have reported positive
correlations between Bag-1 and Bcl-2 expression [56,57,60],
while other workers have made the opposite observation
[42,52]. Some studies have shown no association between
Bag-1 expression and ER or PR expression [58-60], whereas
other studies have shown that Bag-1 and ER do tend to coex-
press [46,52,57], as do Bag-1 and PR [46,57]. These incon-
sistencies could be due to relatively small cohorts, technical
variability in staining from specimen to specimen, and lack of
quantitative measures for immunohistochemistry.
To address these issues, we assessed expression of Bag-1 on
a large cohort of primary breast cancers using tissue microar-
rays, employing a new method of automated, quantitative anal-
ysis. This method has been shown to be more accurate than
pathologist-based scoring of 3,3'-Diaminobenzidine Tetrahy-
drochloride stain (DAB) stain [64], and produces quantitative
measures that are directly proportional to the concentration of
the measured biomarker [65,66]. Since the ER, PR, Her2/neu
and Bcl-2 have prognostic importance in breast cancer and
are also targets of drugs that are in clinical use, we also
assessed the association between Bag-1 expression and
these markers, with the goal of characterizing subsets of
patients based on expression of these biomarkers. We found
that Bag-1 and Bcl-2 tend to be coexpressed, and expression
is correlated with ER and PR expression. Both Bag-1 and Bcl-
2 were associated with improved survival among node-posi-
tive breast cancer patients, particularly those with hormone
receptor-positive tumors.
Materials and methods
Cell lines and western blots
The MDA-MB-468, MCF-7, T47D, BT-474 and SKBR3
(human breast cancer) cell lines were purchased from ATCCAvailable online http://breast-cancer-research.com/content/10/2/R35
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(Manassas, VA, USA). Western blotting of protein extracts
was performed using standard methods. Bag-1 and Bcl-2
expression were detected by overnight incubation with mouse
anti-Bag-1 IgG (Chemicon, Temecula, CA, USA) at 1:400 and
with mouse anti-Bcl-2 IgG (Dako Corp., Carpinteria, CA, USA)
at 1:6,000. Protein loading was assessed using rabbit anti-β-
actin (Sigma-Aldrich, St Louis, MO, USA) at 1:5,000.
Tissue microarray construction
The breast cancer tissue microarrays were constructed as
previously described [67]. A total of 319 node-negative and
319 node-positive breast cancer cores, each measuring 0.6
mm in diameter, were spaced 0.8 mm apart on two glass
slides. The cohort was constructed from paraffin-embedded,
formalin-fixed tissue blocks obtained from the Yale University
Department of Pathology Archives. Specimens and clinical
information were collected under the guidelines and approval
of a Yale University Institutional Review Board.
By standard immunohistochemistry, ER staining was positive
in 52%, PR in 46% and HER2/neu in 14% of specimens.
Nuclear grade 3 (on a 1 to 3 scale) was seen in 28% of the
specimens, and 59% were larger than 2 cm. The histological
subtypes included 72% invasive ductal carcinoma and 1%
lobular carcinoma, and 14% had mixed or other histology. The
specimens were resected between 1962 and 1983, with a fol-
low-up range between 4 months and 53 years, and a mean fol-
low-up time of 12.6 years. Patient age at diagnosis ranged
from 24 to 88 years (mean age, 58 years).
A complete treatment history was not available for the entire
cohort. Most patients were treated with local irradiation. None
of the node-negative patients were given adjuvant systemic
therapy. A minority of the node-positive patients (approxi-
mately 15%) received chemotherapy, and approximately 5.6%
of patients received tamoxifen (postmenopausal patients with
ER-positive tumors, treated after 1978). The time between
tumor resection and tissue fixation was not available.
A pathologist reviewed slides from all of the blocks to select
representative areas of invasive tumor to be cored. The cores
were placed on the tissue microarray using a Tissue Microar-
rayer (Beecher Instruments, Silver Spring, MD, USA). The tis-
sue microarrays were then cut into 0.5 μm sections and were
placed on glass slides using an adhesive tape-transfer system
(Instrumedics, Inc., Hackensack, NJ, USA) with UV cross-link-
ing.
Immunohistochemistry
Staining was performed for automated analysis of breast can-
cer specimens as previously described [68]. Briefly, slides
were deparaffinized in xylene, and were transferred through
two changes of 100% ethanol. For antigen retrieval, the slides
were pressure-cooked in 6.5 mM sodium citrate (pH 6.0).
Endogenous peroxidase activity was blocked in a mixture of
methanol and 2.5% hydrogen peroxide for 30 minutes. To
reduce nonspecific background staining, slides were incu-
bated for 30 minutes in 0.3% bovine serum albumin/1 × Tris-
buffered saline.
Slides were then incubated at 4°C overnight with the following
primary antibodies: mouse monoclonal anti-Bcl-2 (clone 124;
Dako) at 1:40; mouse monoclonal anti-Bag-1 (MAB4611;
Chemicon) at 1:150; mouse monoclonal anti-ER (Dako) at
1:50; mouse monoclonal anti-PR at 1:50 (Dako); and rabbit
anti-Her2/neu at 1:8,000 (Dako). All antibodies were diluted in
Tris-buffered saline containing 0.3% bovine serum albumin.
Goat anti-mouse (or anti-rabbit for Her2/neu) horseradish per-
oxidase-decorated polymer backbone (Envision; Dako) was
used as a secondary reagent, and Cy5-tyramide (Perkin Elmer
Life Science, Waltham, MA, USA) was used to visualize the
target.
To create a tumor mask, primary slides were simultaneously
incubated with rabbit anti-human cytokeratin antibodies
diluted at 1:200. For Bcl-2, Bag-1, ER and PR, rabbit anti-
cytokeratin was used. Mouse anti-cytokeratin was used for
Her2/neu. The anti-cytokeratin antibodies were visualized with
secondary Alexa 488-conjugated goat anti-rabbit or goat anti-
mouse antibodies (Molecular Probes, Inc., Eugene, OR, USA).
Coverslips were mounted with ProLong Gold antifade reagent
with 4',6-diamidino-2-phenylindole (Invitrogen Corp, Grand
Island, NY, USA).
Automated image acquisition
Images were acquired using automated quantitative analysis
(AQUA), as described previously [67]. Briefly, areas of tumor
were distinguished from stroma by creating a mask with the
cytokeratin signal tagged with Alexa 488. Coalescence of
cytokeratin at the cell surface was used to identify the mem-
brane/cytoplasm compartment within the tumor mask, while
4',6-diamidino-2-phenylindole (DAPI) was used to identify the
nuclear compartment within the tumor mask. The target mark-
ers, Bag-1, Bcl-2, ER, PR or Her2/neu, were visualized with
Cy5 (red). Multiple monochromatic, high-resolution (1,024 ×
1,024 pixels, 0.5 μm) grayscale images were obtained for
each histospot, using the 10 × objective of an Olympus AX-51
epifluorescence microscope (Olympus, Melville, NY, USA)
with an automated microscope stage and digital image-acqui-
sition driven by custom program and macro-based interfaces
with IPLabs software (Scanalytics Inc., Fairfax, VA, USA).
Algorithmic image analysis
Images were analyzed using algorithms that have been previ-
ously extensively described [68]. Two images (one in-focus
and one out-of-focus) were taken of the compartment-specific
tags and the target marker. A percentage of the out-of-focus
image was subtracted from the in-focus image for each pixel,
representing the signal-to-noise ratio of the image. An algo-
rithm called the Rapid Exponential Subtraction Algorithm wasBreast Cancer Research    Vol 10 No 2    Nadler et al.
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used to subtract the out-of-focus information in a uniform fash-
ion for the entire microarray. Subsequently, a second algorithm
called the Pixel Locale Assignment for Compartmentalization
of Expression algorithm was used to assign each pixel in the
image to a specific subcellular compartment, and the signal in
each location was calculated. The data were expressed as the
average signal intensity per unit of compartment area on a
scale of 0 to 255, and were expressed as target signal inten-
sity relative to the compartment area.
Statistical analysis
The JMP5 software package (SAS Institute Inc., Cary, NC,
USA) was used for data analysis. Continuous AQUA scores of
target expression were dichotomized by the median score, and
associations with clinical and pathological parameters were
completed using unpaired t tests. The prognostic significance
of the parameters was assessed using the Cox proportional
hazards model with breast cancer-specific survival as an end-
point. Survival curves were generated using the Kaplan–Meier
method, with significance evaluated using the Mantel–Cox
long-rank test. Associations between continuous AQUA
scores for the different markers were assessed by the Spear-
man's rho test.
To generate the principal component analysis biplot (pre-
sented in Figure 1), we tabulated our dataset in a matrix con-
sisting of 439 patients (rows) and five biomarkers (columns).
We only included the 439 patients (out of 638 patients) who
had values for all five biomarkers. The first step in this analysis
involves data preprocessing obtained by first normalizing each
marker 439-dimensional profile by its median value, followed
by a two-way data-centering procedure of this normalized data
matrix. The centering procedure involves transforming each
entry of this matrix by subtraction of the row and column
means of this entry and addition of the overall matrix mean,
leading to a transformed matrix having all row sums and all col-
umn sums equal to zero. Reduction in the number of variables
is useful for visualizing how the patient population is distrib-
uted in the five-dimensional variable space. Principal compo-
nent analysis is an unsupervised dimension reduction method
that generates a new set of decorrelated variables (principal
components) as linear combinations of the original variables
(biomarkers). The majority of the variation associated with the
Her2/neu, ER, PR, Bcl-2 and Bag-1 variables can be captured
by the most dominant principal components. An additional
advantage of expressing the data in terms of the leading prin-
cipal components is their robustness to noise.
The projections of the samples onto the leading principal com-
ponents were computed by applying the singular value
decomposition to the data matrix (after preprocessing as
described above and in previous works [69]). We used princi-
pal component biplots to display the biomarkers (columns of
the data matrix) and the patients (rows of the data matrix)
simultaneously as points in a two-dimensional space [70]. The
biplot provides an optimal approximation of the data matrix by
Figure 1
Principal component analysis and biplot Principal component analysis and biplot. Projection of five-dimensional patient biomarker profiles with no missing data (439 instances) and the 
439-dimensional biomarkers profiles onto the two leading principal components of a matrix consisting of expression profiles of Her2/neu, estrogen 
receptor (ER), progesterone receptor (PR), Bcl-2 and Bcl-2 antanogene-1 (Bag-1) present in all 439 samples. Each patient is represented by a dis-
tinct symbol (￿, alive at 10 years; ×, dead at 10 years). The accumulated variation captured by the first and second principal components is 92% of 
the total variation. Overlaying a two-dimensional scatter plot representing the projection of the biomarkers ( ) onto the first and second principal 
components on top of the two-dimensional patient scatter plot representing the projection of their five-dimensional biomarker profiles onto the two 
leading principal components forms a biplot. The biplot can be used to read the approximated transformed expression levels.
 Available online http://breast-cancer-research.com/content/10/2/R35
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such a two-dimensional structure, in that it displays the singu-
lar value decomposition – which gives the rank-two approxi-
mation to the data matrix having the smallest mean-squared
error. The expression of a given biomarker in a given patient
sample is approximated by the projection of the biomarker vec-
tor onto the direction of the patient sample vector, multiplied
by the length of the patient sample vector. In the present rank-
two approximation, therefore, for a given biomarker and for
patient vectors of a given length, the biomarker is expressed at
a higher (or lower) level in patients whose vector points in
nearly the same (or opposite) direction as the biomarker. A
biomarker is not overexpressed or underexpressed for patients
whose vector is orthogonal to the biomarker vector, and is
underexpressed for patients whose vector form an obtuse
angle with the biomarker vector.
Results
Western blots for Bag-1 and Bcl-2
Western blot analysis for Bag-1 showed bands at 36 kDa, 46
kDa and 50 kDa (Figure 2). These represent the three isoforms
reported in the literature [49], and all three isoforms are recog-
nized by the antibody. The strongest expression of Bag-1 was
observed in BT-474, consistent with findings by other
researchers [42]. For Bcl-2, a single 28 kDa band was seen;
expression was high in the MCF-7 cell line and low in the
SKBR3 cell line, as reported in the literature [26,42,52].
Immunohistochemistry
To account for intratumor heterogeneity, two separate sets of
slides – each containing a core from a different area of the
tumor for each patient – were used to evaluate the expression
of each marker. Bcl-2 and Her2/neu did not have significant
amounts of nuclear staining, and only the membranous/cyto-
plasmic compartments were analyzed, and vice versa, for ER
and PR staining. Bag-1 staining was either nuclear or cyto-
plasmic, and many specimens had both nuclear and cytoplas-
mic staining. We performed log-regression analyses to assess
the correlation between the two slides for Bag-1 and Bcl-2, as
demonstrated in Figure 3. The matching spots on each array
were highly correlated for all four markers (R = 0.6 for Bag-1,
R = 0.7 for Bcl-2, R = 0.74 for the ER, R = 0.79 for the PR
and R = 0.92 for Her2/neu). AQUA scores ranged from 8.3 to
146.02 for the total Bag-1 score (median, 24.07), from 8.37
to 259.61 for Bcl-2 (median, 32.04), from 2.34 to 94.097 for
the PR (median, 6.58), from 1.085 to 61.164 for Her2/neu
(median, 2.03), and from 2.29 to 105.39 for the ER (median,
13.46). Examples of Bag-1 and Bcl-2 staining are shown in
Figure 4.
For each of the markers, the AQUA scores from both sets of
slides were combined to give a single dataset. Tumor spots
were deemed uninterpretable if they had insufficient tumor
cells, loss of tissue in the spot or an abundance of necrotic tis-
sue. For patients who had two interpretable histospots, a com-
posite score was formed by taking the average of the two
scores. For patients with only one interpretable core, the sin-
gle score was used. The combined dataset for Bag-1 had
scores for 574 patients. We obtained scores for Bcl-2, Her2/
Neu, ER and PR for 528 patients, 608 patients, 601 patients
and 595 patients, respectively.
Given that the nodal status often determines the standard clin-
ical approach to patients, we assessed the prognostic value of
Bag-1 and Bcl-2 in the entire cohort, as well as within the
node-positive and node-negative subsets of patients. Using
the Cox univariate survival analysis of raw AQUA scores, we
found that Bag-1 expression (nuclear, cytoplasmic and total)
was associated with breast cancer-specific survival in the
node-positive subset only (P = 0.006 for the total Bag-1
score), whereas Bcl-2 expression was associated with survival
in the entire cohort and in the node-positive subset (P = 0.008
and P = 0.002, respectively). The association with survival for
Bag-1 and Bcl-2 within the node-positive subset (but not the
node-negative subset) might be due to the larger number of
events (deaths) within the node-positive subset.
Table 1 presents the associations between continuous scores
of Bag-1, Bcl-2, ER, PR and Her2/neu and survival in the entire
cohort and in the node-negative and node-positive subsets.
There were no remarkable differences between nuclear Bag-1
scores, cytoplasmic Bag-1 scores and total Bag-1 scores as
predictors of survival; the remainder of these analyses will
therefore focus on the total Bag-1 scores.
Figure 2
Expression of Bcl-2 antanogene-1 isoforms and Bcl-2 Expression of Bcl-2 antanogene-1 isoforms and Bcl-2. Expression 
of Bcl-2 antanogene-1 (Bag-1) isoforms and Bcl-2, using β-actin as a 
loading control in a panel of breast cancer cell lines.Breast Cancer Research    Vol 10 No 2    Nadler et al.
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Continuous AQUA scores were then dichotomized arbitrarily
by the median score, reflecting the use of routine statistical
divisions in the absence of an underlying justification for divi-
sion of expression levels. Kaplan–Meier survival curves were
generated for the total Bag-1 score and Bcl-2, as shown in
Figure 5. The log-rank analysis revealed a statistically signifi-
cant association with survival in the node-positive subset for
Bcl-2 and Bag-1 (P = 0.016 for both markers), and for Bcl-2
in the entire cohort (P = 0.0042).
Using the Cox proportional hazards model, we performed mul-
tivariable analyses to assess the independent prognostic value
of Bag-1 and Bcl-2 expression. Neither of these markers
retained their independent prognostic value in this model, and
the only markers to be independent predictors of survival were
Her2/neu, tumor size and nodal status.
To assess the association between Bag-1 and Bcl-2 expres-
sion and other commonly used clinical and pathological
parameters, we performed analyses of variance. No associa-
tions were found between expression of Bag-1 or Bcl-2 and
nodal status, tumor size, age or nuclear grade.
For patients who had AQUA scores for all five biomarkers, we
assessed the associations between biomarkers by Spear-
man's rho test, as demonstrated in Table 2. Bag-1 and Bcl-2
were strongly correlated with the ER, and with the PR but to a
lesser degree.
Figure 1 shows a principal component biplot, in which both
patient profiles and biomarker profiles are projected onto the
leading principal components. As can be seen, the samples
are distributed in a tree-like branch structure. The samples on
the branch in the positive direction of the first principal compo-
nent are associated with high Her2/neu expression levels and
low to medium levels of ER, PR, Bag-1 and Bcl-2. Similarly, the
samples in the upper left branch have elevated PR expression
levels, low to medium ER, Bcl-2 and Bag-1 expression levels,
and low Her2/neu expression levels. The samples in the lower
left branch have elevated ER, Bcl-2 and Bag-1 levels, low to
medium PR levels, and low Her2/neu levels. The bulk of the
samples are localized next to the origin, and therefore their
inner products with any of the five biomarker vectors are not
high – thus indicating that these patients have median or
below median expression values across all five biomarkers.
Censored patients with less than 10-year follow-up time were
omitted from the biplot. The figure further demonstrates the
strong association between ER, Bag-1 and Bcl-2.
Discussion
In the present work we assessed expression of Bcl-2 and Bag-
1 in primary breast cancer specimens. Consistent with pub-
lished reports, we demonstrated that high Bcl-2 expression is
associated with improved survival and ER-positive and PR-
positive tumors. To the best of our knowledge, this is the first
large cohort study assessing Bag-1 expression and its associ-
ation with Bcl-2, ER, PR and Her2/neu, using continuous out-
put scores, rather than arbitrary pathologist-based divisions of
scores into high/low or strong/weak. We demonstrated an
association between high Bag-1 expression and survival in the
node-positive patients, and found that Bag-1 tends to be coex-
pressed with Bcl-2, ER and PR. Of the markers studied, the
strongest association in expression was found between Bcl-2
and ER. On multivariate analysis, neither Bcl-2 nor Bag-1
retained their independent prognostic value – probably due to
the strong association with ER and PR expression. One prior
report in the literature used a cohort of 920 patients, and
showed that Bcl-2 was an independent prognostic marker.
Figure 3
Regression plot for scores from breast cancer arrays stained for Bcl-2  and Bcl-2 antanogene-1 Regression plot for scores from breast cancer arrays stained for 
Bcl-2 and Bcl-2 antanogene-1. Regression plot for scores from the 
two breast cancer arrays stained for (a) Bcl-2 and (b) Bcl-2 antano-
gene-1 (Bag-1). AQUA, automated quantitative analysis.Available online http://breast-cancer-research.com/content/10/2/R35
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The smaller size of the present cohort might account for our
inability to reproduce this result [6].
Staging of primary breast cancer is performed to determine
prognosis and to select adjuvant therapies, which decrease
the risk of relapse and death. Standard staging criteria are
beneficial for discriminating between patients, but within each
stage group there is variability in outcome and in biological
profiles of tumors. Molecular markers such as Bcl-2 and Bag-
1 expression could supplement our standard staging informa-
tion. Adjuvant chemotherapy decreases the risk of death by
approximately 50% in node-positive patients, and the current
standard of care in the United States includes relatively
aggressive regimens using multiple chemotherapy agents,
usually given in a dose-dense fashion [2,71]. The benefit from
aggressive chemotherapy regimens for node-positive breast
cancer is much lower for patients with hormone receptor-pos-
itive tumors than for those with ER/PR-negative tumors [71].
Markers of improved prognosis (such as Bag-1 and Bcl-2) in
this group of patients could therefore enable us to determine
Figure 4
Immunoflourescent staining of Bcl-2 and Bcl-2 antanogene-1 in breast tumor tissue Immunoflourescent staining of Bcl-2 and Bcl-2 antanogene-1 in breast tumor tissue. (a) Cytoplasmic Bcl-2, (b) cytoplasmic and nuclear Bcl-2 
antanogene-1 (Bag-1) and (c) nuclear Bag-1 staining in a breast cancer histospot – using cytokeratin to the define tumor mask, using 4',6-diamid-
ino-2-phenylindole to define the nuclear compartment, and using Cy5 for identifying the target (Bcl-2 and Bag-1).Breast Cancer Research    Vol 10 No 2    Nadler et al.
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which patients are cured without adjuvant chemotherapy, thus
avoiding the toxicity and cost associated with chemotherapy.
The biological basis for the association between high Bcl-2
and high Bag-1 expression and improved survival has yet to be
determined. Given that both of these proteins are key anti-
apoptotic mediators that are part of the mitochondrial (indi-
rect) pathway [72], one would expect their expression would
be associated with decreased survival, rather than with
increased survival. One plausible explanation is that poorly dif-
ferentiated tumors depend on other prosurvival pathways, and
decreased Bcl-2 and Bag-1 expression is merely a marker of
aggressive tumor behavior rather than mechanistically associ-
ated with aggressive biology. Breast cancer studies in the lit-
erature have consistently demonstrated an association
between high Bcl-2 expression and improved survival [4-24],
and similar findings have been demonstrated in other diseases
[73].
Another possible explanation for our findings is that in good-
prognosis breast cancer tumors, Bcl-2 and Bag-1 have other
dominant roles that are not related to their anti-apoptotic func-
tions. For example, studies have shown that high levels of Bcl-
2 actually inhibit cell growth [74,75]. Most of the literature,
however, supports an anti-apoptotic role of Bcl-2 and Bag-1 in
early-stage breast cancer, which appears to be related to the
transcriptional function of ER. Nuclear Bag-1 stimulates the
activity of the α and β subunits of the ER [46], and this might
be the basis for coexpression of ER and Bag-1 in human
tumors. The PR is a transcriptional target of the ER, and would
thus similarly be expected to have coexpression with Bag-1.
ER transcriptional activity results in Bcl-2 upregulation in
breast cancer, and both ER and Bcl-2 are associated with
chemotherapy resistance in breast cancer [76,77]. The strong
association between ER, PR, Bcl-2 and Bag-1 in our study
suggests that co-targeting these molecules in hormone recep-
tor-positive breast cancer might provide greater benefit than
chemotherapy, or might be a beneficial strategy for sensitizing
these tumors to chemotherapy – including in the node-positive
subset of patients.
Drugs that target Bcl-2 are already in clinical trials. Antisense
to Bcl-2 has activity in breast cancer in preclinical models as a
single agent and also sensitizes high Bcl-2-expressing cells to
a range of chemotherapeutic agents [26]. A randomized clini-
cal trial for metastatic melanoma comparing dacarbazine alone
with dacarbazine and Bcl-2 antisense demonstrated an
increase in response rates and improved survival in patients
with less aggressive disease, but not in patients with more
aggressive disease (as assessed by levels of lactate dehydro-
genase (LDH) [78]. Unfortunately, expression of Bcl-2 was not
assessed in this clinical trial; however, previous studies on
metastatic melanoma specimens suggest that patients with
more advanced disease have significantly lower levels of Bcl-
2 expression [73]. Additional small-molecule inhibitors that tar-
get Bcl-2 are currently being studied [79,80]. Attempts at
targeting Bag-1 as a sensitizer to chemotherapy are in their
infancy [81], and our data suggest that combinations of anti-
hormonal therapy with drugs that target Bcl-2 and/or Bag-1
should also be investigated, particularly in patients with high
Bcl-2 or Bag-1 levels.
Conclusion
In summary, using an automated quantitative method of pro-
tein expression analysis to study a large cohort of primary
tumors, we have shown that both Bcl-2 and Bag-1 are associ-
ated with improved survival in node-positive breast cancer,
and that both Bcl-2 and Bag-1 are strongly associated with ER
and PR expression. Targeting Bcl-2 and/or Bag-1 in node-
positive, hormone receptor-positive breast cancer might
improve the therapeutic ratio of adjuvant therapy in this popu-
lation. Future clinical trials using agents that target Bcl-2 and/
or Bag-1 in breast cancer should focus on hormone receptor-
positive patients, and all studies should incorporate assess-
ment of target expression in pretreatment tumors to assess the
association between target expression and response to
therapy.
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receptor
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Figure 5
Kaplan–Meier survival curves for Bcl-2 and Bcl-2 antanogene-1 Kaplan–Meier survival curves for Bcl-2 and Bcl-2 antanogene-1. Kaplan–Meier survival curves for Bcl-2 and Bcl-2 antanogene-1 (Bag-1) auto-
mated quantitative analysis scores dichotomized by the median score for (a) the entire cohort of patients, (b) node-negative patients, and (c) node-
positive patients.
Table 2
Spearman's rho associations between expression of Her2/neu, estrogen receptor, progesterone receptor Bcl-2 antanogene-1 (Bag-
1) and Bcl-2
Estrogen receptor Progesterone receptor Bag-1 Bcl-2
Her2/neu -0.0093, P = 0.82 (-0.0897 
to 0.0712)
-0.066, P = 0.93 (-0.146 to 
0.0149)
0.0617, P = 0.1430 (-
0.0209 to 0.1436)
-0.0379, P = 0.3885 (-
0.1234 to 0.0482)
Estrogen receptor 0.4942, P < 0.0001 (0.4304 
to 0.5531)
0.4150, P < 0.0001 (0.3438 
to 0.4814)
0.5459, P < 0.0001 (0.4824 
to 0.6036)
Progesterone receptor 0.2260, P < 0.0001 (0.1456 
to 0.3035)
0.3661, P < 0.0001 (0.2889 
to 0.4385)
Bag-1 0.3050, P < 0.0001 (0.2228 
to 0.3830)
Data in bold are significant (P < 0.05). Data in parentheses represent the 95% confidence intervals.Breast Cancer Research    Vol 10 No 2    Nadler et al.
Page 10 of 12
(page number not for citation purposes)
given exclusive rights to produce and distribute software and
technologies embedded in AQUA. Yale University retains pat-
ent rights for the AQUA technology. The other authors declare
that they have no competing interests.
Authors' contributions
HMK and YK contributed equally to this work. YK and HMK ini-
tiated the project, performed all the computational aspects of
the projects and drafted the manuscript. YN performed the
experiments for BAG-1 and Bcl-2, and assisted in drafting the
manuscript. RLC and DLR developed the AQUA technology.
JMG and CM performed the AQUA analysis for Her2, ER and
PR. All authors read and approved the manuscript.
Acknowledgements
This work was supported by a grant from the Susan G. Komen Founda-
tion (to YK). HMK is supported by the Susan G. Komen Foundation and 
the Breast Cancer Alliance.
References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer sta-
tistics, 2007.  CA Cancer J Clin 2007, 57:43-66.
2. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar
WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Car-
penter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH,
Abrams J, Schilsky RL, Muss HB, Norton L: Randomized trial of
dose-dense versus conventionally scheduled and sequential
versus concurrent combination chemotherapy as postopera-
tive adjuvant treatment of node-positive primary breast can-
cer: first report of Intergroup Trial C9741/Cancer and
Leukemia Group B Trial 9741.  J Clin Oncol 2003,
21:1431-1439.
3. Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM,
Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass
AG:  Postoperative chemotherapy and tamoxifen compared
with tamoxifen alone in the treatment of positive-node breast
cancer patients aged 50 years and older with tumors respon-
sive to tamoxifen: results from the National Surgical Adjuvant
Breast and Bowel Project B-16.  J Clin Oncol 1990,
8:1005-1018.
4. Bilalovic N, Vranic S, Hasanagic S, Basic H, Tatarevic A, Beslija S,
Selak I: The Bcl-2 protein: a prognostic indicator strongly
related to ER and PR in breast cancer.  Bosn J Basic Med Sci
2004, 4:5-12.
5. Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W:
Bcl-2 protein expression in breast cancer in relation to estab-
lished prognostic factors and other clinicopathological
variables.  Ann Oncol 1995, 6:1005-1010.
6. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz
J, Ellis IO, Huntsman D, Caldas C: Bcl-2 is a prognostic marker
in breast cancer independently of the Nottingham Prognostic
Index.  Clin Cancer Res 2006, 12:2468-2475.
7. Dimitrakakis C, Konstadoulakis M, Messaris E, Kymionis G, Karay-
annis M, Panoussopoulos D, Michalas S, Androulakis G: Molecu-
lar markers in breast cancer: can we use c-erbB-2, p53, bcl-2
and bax gene expression as prognostic factors?  Breast 2002,
11:279-285.
8. Gaballah HE, Abdel Salam I, Abdel Wahab N, Mansour OM:
Plasma bcl-2 and nitric oxide: possible prognostic role in
patients with metastatic breast cancer.  Med Oncol 2001,
18:171-178.
9. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle
HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI: Immunocyto-
chemical localization of BCL-2 protein in human breast can-
cers and its relationship to a series of prognostic markers and
response to endocrine therapy.  Int J Cancer 1994, 59:619-628.
10. Hellemans P, van Dam PA, Weyler J, van Oosterom AT, Buytaert
P, Van Marck E: Prognostic value of bcl-2 expression in inva-
sive breast cancer.  Br J Cancer 1995, 72:354-360.
11. Jansen RL, Joosten-Achjanie SR, Volovics A, Arends JW, Hup-
perets PS, Hillen HF, Schouten HC: Relevance of the expression
of bcl-2 in combination with p53 as a prognostic factor in
breast cancer.  Anticancer Res 1998, 18:4455-4462.
12. Kapranos N, Karaiosifidi H, Valavanis C, Kouri E, Vasilaros S:
Prognostic significance of apoptosis related proteins Bcl-2
and Bax in node-negative breast cancer patients.  Anticancer
Res 1997, 17:2499-2505.
13. Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim
TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ: Prognostic sig-
nificance of bcl-2 expression in stage III breast cancer patients
who had received doxorubicin and cyclophosphamide fol-
lowed by paclitaxel as adjuvant chemotherapy.  BMC Cancer
2007, 12():7-63.
14. Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S:
Prognostic significance of p53, bcl-2, and Bax expression in
early breast cancer.  J Am Coll Surg 2004, 198:83-90.
15. Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotirop-
oulou M, Vlachodimitropoulos D, Papadopoulos S, Tzaida O, Kafiri
G, Kyriakou V, Markaki S, Papaspyrou I, Karagianni E, Pavlakis K,
Toliou T, Scopa C, Papakostas P, Bafaloukos D, Christodoulou C,
Fountzilas G: Evaluation of the prognostic and predictive value
of p53 and Bcl-2 in breast cancer patients participating in a
randomized study with dose-dense sequential adjuvant
chemotherapy.  Ann Oncol 2006, 17:1504-1511.
16. Mauri FA, Maisonneuve P, Caffo O, Veronese S, Aldovini D, Fer-
rero S, Cozzaglio F, Dalla Palma P, Galligioni E, Barbareschi M:
Prognostic value of estrogen receptor status can be improved
by combined evaluation of p53, Bcl2 and PgR expression: an
immunohistochemical study on breast carcinoma with long-
term follow-up.  Int J Oncol 1999, 15:1137-1147.
17. McLaughlin R, O'Hanlon D, McHale T, Connolly CE, Given HF:
Prognostic implications of p53 and bcl-2 expression in 108
women with stage two breast cancer.  Ir J Med Sci 2001,
170:11-13.
18. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mez-
zetti M, Di Fronzo G, Rilke F, Veronesi U: The Bcl-2 protein: a
prognostic indicator strongly related to p53 protein in lymph
node-negative breast cancer patients.  J Natl Cancer Inst 1994,
86:499-504.
19. Sirvent JJ, Aguilar MC, Olona M, Pelegri A, Blazquez S, Gutierrez
C: Prognostic value of apoptosis in breast cancer (pT1–pT2).
A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical
study.  Histol Histopathol 2004, 19:759-770.
20. Thomadaki H, Talieri M, Scorilas A: Prognostic value of the apop-
tosis related genes BCL2 and BCL2L12 in breast cancer.  Can-
cer Lett 2007, 247:48-55.
21. Trere D, Montanaro L, Ceccarelli C, Barbieri S, Cavrini G, Santini
D, Taffurelli M, Derenzini M: Prognostic relevance of a novel
semiquantitative classification of Bcl2 immunohistochemical
expression in human infiltrating ductal carcinomas of the
breast.  Ann Oncol 2007, 18:1004-1014.
22. van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud
C, Mandard AM, Delobelle-Deroide A, Velde CJ van de, Vijver MJ
van de: Expression of Bcl-2 in node-negative breast cancer is
associated with various prognostic factors, but does not pre-
dict response to one course of perioperative chemotherapy.
Br J Cancer 1996, 74:78-85.
23. Yang Q, Sakurai T, Yoshimura G, Suzuma T, Umemura T, Naka-
mura M, Nakamura Y, Mori I, Kakudo K: Prognostic value of Bcl-
2 in invasive breast cancer receiving chemotherapy and endo-
crine therapy.  Oncol Rep 2003, 10:121-125.
24. Zhang GJ, Tsuda H, Adachi I, Fukutomi T, Yamamoto H, Hirohashi
S: Prognostic indicators for breast cancer patients with one to
three regional lymph node metastases, with special reference
to alterations in expression levels of bcl-2, p53 and c-erbB-2
proteins.  Jpn J Clin Oncol 1997, 27:371-377.
25. Adams JM, Cory S: The Bcl-2 protein family: arbiters of cell
survival.  Science 1998, 281:1322-1326.
26. Emi M, Kim R, Tanabe K, Uchida Y, Toge T: Targeted therapy
against Bcl-2-related proteins in breast cancer cells.  Breast
Cancer Res 2005, 7:R940-R952.
27. Bhargava V, Kell DL, Rijn M van de, Warnke RA: Bcl-2 immuno-
reactivity in breast carcinoma correlates with hormone recep-
tor positivity.  Am J Pathol 1994, 145:535-540.
28. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale
G: The prevalence of BCL-2 immunoreactivity in breast carci-Available online http://breast-cancer-research.com/content/10/2/R35
Page 11 of 12
(page number not for citation purposes)
nomas and its clinicopathological correlates, with particular
reference to oestrogen receptor status.  Virchows Arch 1994,
424:47-51.
29. Lee WY, Jin YT, Tzeng CC: Reciprocal expression of Bcl-2 and
p53 in breast ductal carcinoma.  Anticancer Res 1996,
16:3007-3012.
30. Sierra A, Lloveras B, Castellsague X, Moreno L, Garcia-Ramirez M,
Fabra A: Bcl-2 expression is associated with lymph node
metastasis in human ductal breast carcinoma.  Int J Cancer
1995, 60:54-60.
31. Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Lavaut MN,
Allasia C: Automated and quantitative immunocytochemical
assays of Bcl-2 protein in breast carcinomas.  Br J Cancer
1997, 76:340-346.
32. Diaz-Cano SJ, Garcia-Moliner M, Carney W, Wolfe HJ: Bcl-2
expression and DNA fragmentation in breast carcinoma, path-
ologic and steroid hormone receptors correlates.  Diagn Mol
Pathol 1997, 6:199-208.
33. Lee HD, Koo JY, Jung WH: Correlations of bcl-2 expression with
clinicopathological features in breast cancer.  Yonsei Med J
1997, 38:206-211.
34. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK,
Allred DC: bcl-2 and apoptosis in lymph node positive breast
carcinoma.  Cancer 1998, 82:1296-1302.
35. Magro G, Bisceglia M, Michal M: Expression of steroid hormone
receptors, their regulated proteins, and bcl-2 protein in myofi-
broblastoma of the breast.  Histopathology 2000, 36:515-521.
36. Kymionis GD, Dimitrakakis CE, Konstadoulakis MM, Arzimanoglou
I, Leandros E, Chalkiadakis G, Keramopoulos A, Michalas S: Can
expression of apoptosis genes, bcl-2 and bax, predict survival
and responsiveness to chemotherapy in node-negative breast
cancer patients?  J Surg Res 2001, 99:161-168.
37. Martinez-Arribas F, Nunez-Villar MJ, Lucas AR, Sanchez J, Tejerina
A, Schneider J: Immunofluorometric study of Bcl-2 and Bax
expression in clinical fresh tumor samples from breast cancer
patients.  Anticancer Res 2003, 23:565-568.
38. Martinez-Arribas F, Alvarez T, Del Val G, Martin-Garabato E,
Nunez-Villar MJ, Lucas R, Sanchez J, Tejerina A, Schneider J: Bcl-
2 expression in breast cancer: a comparative study at the
mRNA and protein level.  Anticancer Res 2007, 27:219-222.
39. Kumaravel B, Arihiro K, Kaneko M, Fujii S, Inai K: Expression of
bcl-2 protein in breast carcinoma with correlation to expres-
sion of p53 protein and clinicopathological factors.  Breast
Cancer 1996, 3:173-179.
40. O'Driscoll L, Linehan R, S MK, Cronin D, Purcell R, Glynn S, E WM,
A DH, N JOH, Parkinson M, Clynes M: Lack of prognostic signif-
icance of survivin, survivin-deltaEx3, survivin-2B, galectin-3,
bag-1, bax-alpha and MRP-1 mRNAs in breast cancer.  Cancer
Lett 2003, 201:225-236.
41. Kroger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schu-
macher M, Zander AR, Loning T: Prognostic and predictive
effects of immunohistochemical factors in high-risk primary
breast cancer patients.  Clin Cancer Res 2006, 12:159-168.
42. Yang X, Hao Y, Ding Z, Pater A, Tang SC: Differential expression
of antiapoptotic gene BAG-1 in human breast normal and can-
cer cell lines and tissues.  Clin Cancer Res 1999, 5:1816-1822.
43. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed
JC: Cloning and functional analysis of BAG-1: a novel Bcl-2-
binding protein with anti-cell death activity.  Cell 1995,
80:279-284.
44. Bardelli A, Longati P, Albero D, Goruppi S, Schneider C, Ponzetto
C, Comoglio PM: HGF receptor associates with the anti-apop-
totic protein BAG-1 and prevents cell death.  Embo J 1996,
15:6205-6212.
45. Takayama S, Reed JC: Molecular chaperone targeting and reg-
ulation by BAG family proteins.  Nat Cell Biol 2001,
3:E237-E241.
46. Cutress RI, Townsend PA, Sharp A, Maison A, Wood L, Lee R,
Brimmell M, Mullee MA, Johnson PW, Royle GT, Bateman AC,
Packham G: The nuclear BAG-1 isoform, BAG-1L, enhances
oestrogen-dependent transcription.  Oncogene 2003,
22:4973-4982.
47. Townsend PA, Stephanou A, Packham G, Latchman DS: BAG-1:
a multi-functional pro-survival molecule.  Int J Biochem Cell
Biol 2005, 37:251-259.
48. Tang SC: BAG-1, an anti-apoptotic tumour marker.  IUBMB Life
2002, 53:99-105.
49. Yang X, Chernenko G, Hao Y, Ding Z, Pater MM, Pater A, Tang
SC: Human BAG-1/RAP46 protein is generated as four iso-
forms by alternative translation initiation and overexpressed in
cancer cells.  Oncogene 1998, 17:981-989.
50. Packham G, Brimmell M, Cleveland JL: Mammalian cells express
two differently localized Bag-1 isoforms generated by alterna-
tive translation initiation.  Biochem J 1997, 328(Pt 3):807-813.
51. Coldwell MJ, deSchoolmeester ML, Fraser GA, Pickering BM,
Packham G, Willis AE: The p36 isoform of BAG-1 is translated
by internal ribosome entry following heat shock.  Oncogene
2001, 20:4095-4100.
52. Brimmell M, Burns JS, Munson P, McDonald L, O'Hare MJ, Lakhani
SR, Packham G: High level expression of differentially local-
ized BAG-1 isoforms in some oestrogen receptor-positive
human breast cancers.  Br J Cancer 1999, 81:1042-1051.
53. Cutress RI, Townsend PA, Bateman AC, Johnson PW, Ryder K,
Barnes DM, Packham G: BAG-1 immunostaining and survival in
early breast cancer.  J Clin Oncol 2001, 19:3706-3707.
54. Krajewski S, Krajewska M, Turner BC, Pratt C, Howard B, Zapata
JM, Frenkel V, Robertson S, Ionov Y, Yamamoto H, Perucho M,
Takayama S, Reed JC: Prognostic significance of apoptosis
regulators in breast cancer.  Endocr Relat Cancer 1999,
6:29-40.
55. Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ,
Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S,
Reed JC, Bast RC Jr, Hortobagyi GN: Expression of BAG-1 and
BcL-2 proteins before and after neoadjuvant chemotherapy of
locally advanced breast cancer.  Cancer Invest 2004,
22:248-256.
56. Sjostrom J, Blomqvist C, von Boguslawski K, Bengtsson NO, Mjaa-
land I, Malmstrom P, Ostenstadt B, Wist E, Valvere V, Takayama S,
Reed JC, Saksela E: The predictive value of bcl-2, bax, bcl-xL,
bag-1, fas, and fasL for chemotherapy response in advanced
breast cancer.  Clin Cancer Res 2002, 8:811-816.
57. Tang SC, Beck J, Murphy S, Chernenko G, Robb D, Watson P,
Khalifa M: BAG-1 expression correlates with Bcl-2, p53, differ-
entiation, estrogen and progesterone receptors in invasive
breast carcinoma.  Breast Cancer Res Treat 2004, 84:203-213.
58. Tang SC, Shehata N, Chernenko G, Khalifa M, Wang X: Expres-
sion of BAG-1 in invasive breast carcinomas.  J Clin Oncol
1999, 17:1710-1719.
59. Townsend PA, Dublin E, Hart IR, Kao RH, Hanby AM, Cutress RI,
Poulsom R, Ryder K, Barnes DM, Packham G: BAG-i expression
in human breast cancer: interrelationship between BAG-1
RNA, protein, HSC70 expression and clinico-pathological data.
J Pathol 2002, 197:51-59.
60. Turner BC, Krajewski S, Krajewska M, Takayama S, Gumbs AA,
Carter D, Rebbeck TR, Haffty BG, Reed JC: BAG-1: a novel
biomarker predicting long-term survival in early-stage breast
cancer.  J Clin Oncol 2001, 19:992-1000.
61. Townsend PA, Cutress RI, Sharp A, Brimmell M, Packham G:
BAG-1 prevents stress-induced long-term growth inhibition in
breast cancer cells via a chaperone-dependent pathway.  Can-
cer Res 2003, 63:4150-4157.
62. Kudoh M, Knee DA, Takayama S, Reed JC: Bag1 proteins regu-
late growth and survival of ZR-75-1 human breast cancer cells.
Cancer Res 2002, 62:1904-1909.
63. Zapata JM, Krajewska M, Krajewski S, Huang RP, Takayama S,
Wang HG, Adamson E, Reed JC: Expression of multiple apop-
tosis-regulatory genes in human breast cancer cell lines and
primary tumors.  Breast Cancer Res Treat 1998, 47:129-140.
64. Camp RL, Dolled-Filhart M, King BL, Rimm DL: Quantitative anal-
ysis of breast cancer tissue microarrays shows that both high
and normal levels of HER2 expression are associated with
poor outcome.  Cancer Res 2003, 63:1445-1448.
65. Dolled-Filhart M, McCabe A, Giltnane J, Cregger M, Camp RL,
Rimm DL: Quantitative in situ analysis of beta-catenin expres-
sion in breast cancer shows decreased expression is associ-
ated with poor outcome.  Cancer Res 2006, 66:5487-5494.
66. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL: Automated
quantitative analysis (AQUA) of in situ protein expression,
antibody concentration, and prognosis.  J Natl Cancer Inst
2005, 97:1808-1815.
67. Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL,
Rimm DL: Macrophage colony-stimulating factor-1 receptor
expression is associated with poor outcome in breast cancerBreast Cancer Research    Vol 10 No 2    Nadler et al.
Page 12 of 12
(page number not for citation purposes)
by large cohort tissue microarray analysis.  Clin Cancer Res
2004, 10(1 Pt 1):173-177.
68. Camp RL, Chung GG, Rimm DL: Automated subcellular locali-
zation and quantification of protein expression in tissue
microarrays.  Nat Med 2002, 8:1323-1327.
69. Kluger Y, Tuck DP, Chang JT, Nakayama Y, Poddar R, Kohya N,
Lian Z, Ben Nasr A, Halaban HR, Krause DS, Zhang X, Newburger
PE, Weissman SM: Lineage specificity of gene expression
patterns.  Proc Natl Acad Sci USA 2004, 101:6508-6513.
70. Cox TFC, Cox AA: Multidimensional Scaling London: Chapman &
Hall; 2001. 
71. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR,
Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C,
Winer EP: Estrogen-receptor status and outcomes of modern
chemotherapy for patients with node-positive breast cancer.
JAMA 2006, 295:1658-1667.
72. Hengartner MO: The biochemistry of apoptosis.  Nature 2000,
407:770-776.
73. Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger
HM:  Automated quantitative analysis of tissue microarrays
reveals an association between high Bcl-2 expression and
improved outcome in melanoma.  Cancer Res 2004,
64:8773-8777.
74. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler
KW, Vogelstein B: Paradoxical inhibition of solid tumor cell
growth by bcl2.  Cancer Res 1994, 54:3714-3717.
75. Knowlton K, Mancini M, Creason S, Morales C, Hockenbery D,
Anderson BO: Bcl-2 slows in vitro breast cancer growth
despite its antiapoptotic effect.  J Surg Res 1998, 76:22-26.
76. Teixeira C, Reed JC, Pratt MA: Estrogen promotes chemothera-
peutic drug resistance by a mechanism involving Bcl-2 proto-
oncogene expression in human breast cancer cells.  Cancer
Res 1995, 55:3902-3907.
77. Daidone MG, Luisi A, Veneroni S, Benini E, Silvestrini R: Clinical
studies of Bcl-2 and treatment benefit in breast cancer
patients.  Endocr Relat Cancer 1999, 6:61-68.
78. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M,
Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood
JM, Haluska FG: Bcl-2 antisense (oblimersen sodium) plus
dacarbazine in patients with advanced melanoma: the Oblim-
ersen Melanoma Study Group.  J Clin Oncol 2006,
24:4738-4745.
79. Mohammad RM, Wang S, Aboukameel A, Chen B, Wu X, Chen J,
Al-Katib A: Preclinical studies of a nonpeptidic small-molecule
inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse
large cell lymphoma.  Mol Cancer Ther 2005, 4:13-21.
80. Li J, Viallet J, Haura EB: A small molecule pan-Bcl-2 family inhib-
itor, GX15-070, induces apoptosis and enhances cisplatin-
induced apoptosis in non-small cell lung cancer cells.  Cancer
Chemother Pharmacol 2008, 61:525-534.
81. Xiong J, Chen J, Chernenko G, Beck J, Liu H, Pater A, Tang SC:
Antisense BAG-1 sensitizes HeLa cells to apoptosis by multi-
ple pathways.  Biochem Biophys Res Commun 2003,
312:585-591.